Zavegepant (BHV-3500)

DRUG2 trials

Sponsors

Pfizer

Conditions

Acute MigraineCOVID-19 Infection

Phase 2

Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

TerminatedNCT04346615

PfizerCOVID-19 Infection

Start: 2020-04-25End: 2022-04-29Updated: 2024-05-02

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

CompletedNCT04408794

PfizerAcute Migraine

Start: 2020-06-29End: 2021-12-23Updated: 2023-05-18

Related Papers

Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study.

2025-12-11

Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study

Cephalalgia2024-08-0110 citations

Long-Term Safety and Tolerability of Zavegepant 10 mg Nasal Spray During Concomitant Use of CGRP Monoclonal Antibodies: Results From a 1-Year Open-label Safety Trial (P10-12.009)

Neurology2023-04-253 citations

A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine (P9-12.002)

Neurology2023-04-252 citations